title: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).
abstract: OBJECTIVE
  A multi-centric trial was performed to explore the clinical activity, in terms of response and toxicity (primary objectives), duration of response and survival (secondary objectives), of docetaxel with cisplatin in advanced gastric cancer (AGC).
  
  
  METHODS
  Patients with measurable unresectable and/or metastatic gastric carcinoma, performance status < or = 1, normal hematological, hepatic and renal functions and not pretreated for advanced disease by chemotherapy received up to eight cycles of TC (docetaxel 85 mg/m2 dl, cisplatin 75 mg/m2 dl) q3w. Dose escalation to 100 mg/m2 was performed in five patients and was discontinued for excessive toxicity.
  
  
  RESULTS
  Forty-eight patients were accrued. A median of 5 cycles/patient was given. We observed 2 complete and 25 partial responses for an overall intent to treat response rate of 56% (95% CI: 41%-71%). Twelve patients had stable disease for > or = 9 weeks (3 cycles). The median time to progression and overall survival were 6.6 and 9 months, respectively. Grade > or = 3 toxicities were neutropenia 81%, anemia 32%, thrombocytopenia 4%, alopecia 36%, fatigue 9%, mucositis 9%, diarrhea 6%, nausea/vomiting 4%, neurologic 2%, and one anaphylaxis precluding treatment administration. We recorded nine episodes of non-fatal febrile neutropenia in eight patients, two of them with docetaxel at 100 mg/m2. There were no direct treatment-related deaths.
  
  
  CONCLUSIONS
  TC is active in AGC with a high response rate in a multicentric trial. Despite its hematotoxicity, this regimen is well tolerated and can be recycled as originally planned in 78% of the cases. These results may serve as basis for further developments of docetaxel containing regimens in this disease.
authors.affiliation: Department of Surgery, Hôpital Cantonal Universitaire, Geneva, Switzerland. arnaud.roth@dim.hcuge.ch
authors.forename: A D
authors.initials: AD
authors.lastname: Roth
authors.forename: R
authors.initials: R
authors.lastname: Maibach
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: N
authors.initials: N
authors.lastname: Fazio
authors.forename: M S
authors.initials: MS
authors.lastname: Aapro
authors.forename: O
authors.initials: O
authors.lastname: Pagani
authors.forename: R
authors.initials: R
authors.lastname: Morant
authors.forename: M M
authors.initials: MM
authors.lastname: Borner
authors.forename: R
authors.initials: R
authors.lastname: Herrmann
authors.forename: H
authors.initials: H
authors.lastname: Honegger
authors.forename: F
authors.initials: F
authors.lastname: Cavalli
authors.forename: P
authors.initials: P
authors.lastname: Alberto
authors.forename: M
authors.initials: M
authors.lastname: Castiglione
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D000077143:Docetaxel; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016019:Survival Analysis; D043823:Taxoids
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin